MedMatrix Rx
Daily 340B Morning Briefing for Executives
The 340B program faces significant challenges as federal policies and drug pricing trends reshape its landscape. The Inflation Reduction Act’s impact on 340B margins is evident, with health centers particularly affected. Meanwhile, Johnson & Johnson’s new claims data requirement for 340B pricing adds pressure on covered entities. The American Hospital Association is pushing for a permanent ban on rebate models within the program. These developments highlight the evolving complexities and financial pressures within the 340B ecosystem.
EXECUTIVE SUMMARY
01
340B Margins Squeezed by Federal Policies.
New federal policies and IRA-negotiated drug prices are reducing 340B savings, impacting health centers more than hospitals.
New federal policies and IRA-negotiated drug prices are reducing 340B savings, impacting health centers more than hospitals.
Source: Drug Channels
02
J&J Requires Claims Data for 340B Pricing.
Johnson & Johnson mandates claims-level data submission for 340B pricing, with noncompliance leading to pricing suspension.
Johnson & Johnson mandates claims-level data submission for 340B pricing, with noncompliance leading to pricing suspension.
Source: Becker’s Hospital Review
03
AHA Seeks Permanent 340B Rebate Ban.
The American Hospital Association urges Congress to permanently bar rebate models in the 340B program, citing operational burdens.
The American Hospital Association urges Congress to permanently bar rebate models in the 340B program, citing operational burdens.
Source: Becker’s Hospital Review
04
340B Hospitals Report Less Charity Care.
A report shows 340B hospitals spend less on charity care than non-340B hospitals, raising concerns about the program’s impact.
A report shows 340B hospitals spend less on charity care than non-340B hospitals, raising concerns about the program’s impact.
Source: Becker’s Hospital Review
05
NASP Comments on CMS 340B Payment Changes.
NASP submitted comments on CMS’ proposed changes to Medicare reimbursement for 340B-acquired drugs, focusing on compliance and access.
NASP submitted comments on CMS’ proposed changes to Medicare reimbursement for 340B-acquired drugs, focusing on compliance and access.
Source: NASP
06
ASHP Advocates for 340B Program Protections.
ASHP members lobby Congress for expanded Medicare coverage and protections for the 340B Drug Pricing Program.
ASHP members lobby Congress for expanded Medicare coverage and protections for the 340B Drug Pricing Program.
Source: Becker’s Hospital Review
07
340B Rebate Pilot to Start in 2027.
A federal rebate pilot for 340B pricing is set to begin in 2027. It will improve transparency and prevent duplicate discounts.
A federal rebate pilot for 340B pricing is set to begin in 2027. It will improve transparency and prevent duplicate discounts.
Source: Becker’s Hospital Review
08
Milliman Analyzes IRA Impact on Part D.
Milliman reports the IRA has significantly increased the direct subsidy for Medicare Part D, affecting funding mechanics.
Milliman reports the IRA has significantly increased the direct subsidy for Medicare Part D, affecting funding mechanics.
Source: Drug Channels
09
340B Litigation Continues Nationwide.
Numerous legal battles over 340B program aspects, including contract pharmacy access and reimbursement practices, are ongoing.
Numerous legal battles over 340B program aspects, including contract pharmacy access and reimbursement practices, are ongoing.
Source: Becker’s Hospital Review
10
Federal Court Allows Intervention in AbbVie Suit.
A federal judge permits health groups to intervene in AbbVie’s lawsuit challenging HHS’ 340B patient definition.
A federal judge permits health groups to intervene in AbbVie’s lawsuit challenging HHS’ 340B patient definition.
Source: Becker’s Hospital Review
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The shrinking margins for 340B covered entities due to federal policies and drug pricing changes could lead to financial instability for health centers. As the Inflation Reduction Act continues to influence drug pricing, the pressure on 340B savings intensifies. Health centers, which rely more heavily on Part D drugs, may face greater challenges than hospitals. This trend could force covered entities to reassess their financial strategies and operations to maintain service levels and sustainability.
Emerging risks.
- 340B covered entities face financial pressure from reduced savings due to federal policies.
- Johnson & Johnson’s claims data requirement adds compliance burdens for 340B providers.
- Potential permanent rebate ban could alter 340B program operations and increase administrative costs.
- Legal challenges and policy changes could disrupt 340B drug pricing and access for covered entities.
Emerging opportunities.
- Covered entities can explore alternative revenue streams to offset reduced 340B savings.
- Advocacy for program protections may influence legislative outcomes favorably for 340B participants.
- Engagement in policy discussions can help shape future 340B program rules and regulations.
- Participation in the 340B rebate pilot could improve transparency and operational efficiency.
Key actions for providers.
- Monitor federal policy changes and their impact on 340B margins and operations.
- Ensure compliance with new claims data requirements to maintain 340B pricing access.
- Advocate for favorable legislative outcomes regarding 340B program protections and rebate models.
- Prepare for potential operational adjustments due to legal and policy developments in the 340B space.
TOP STORIES
340B Margins Squeezed by Federal Policies.
Drug Channels · September 29, 2026
- New federal policies and IRA-negotiated drug prices are reducing 340B savings.
- Health centers are more affected than hospitals due to reliance on Part D drugs.
- The shrinking 340B ceiling price impacts financial stability for covered entities.
J&J Requires Claims Data for 340B Pricing.
Becker’s Hospital Review · September 11, 2026
- Johnson & Johnson mandates claims-level data submission for 340B pricing.
- Noncompliance results in pricing suspension after multiple notices.
- Policy applies to all covered entity types regardless of location.
AHA Seeks Permanent 340B Rebate Ban.
Becker’s Hospital Review · September 25, 2026
- AHA urges Congress to bar rebate models in the 340B program permanently.
- The SECURE 340B Act includes protections and new requirements for hospitals.
- AHA warns of administrative and financial burdens from proposed changes.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
NASP Comments on CMS 340B Payment Changes.
NASP · September 1, 2026
- NASP submitted comments on CMS’ proposed changes to 340B reimbursement.
- Focus on compliance, operational, and access implications for specialty pharmacies.
- Comments address potential impacts on patient access and program administration.
ASHP Advocates for 340B Program Protections.
Becker’s Hospital Review · September 16, 2026
- ASHP members lobby Congress for expanded Medicare coverage and 340B protections.
- Legislation seeks direct Medicare coverage for pharmacist-provided care.
- ASHP emphasizes the importance of pharmacy residency training.
Federal Court Allows Intervention in AbbVie Suit.
Becker’s Hospital Review · September 1, 2026
- A federal judge allows health groups to intervene in AbbVie’s lawsuit.
- The case challenges HHS’ definition of ‘patient’ under the 340B statute.
- Intervention supports the government’s long-standing interpretation.
340B PROGRAM DEVELOPMENTS
340B Hospitals Report Less Charity Care.
Becker’s Hospital Review · September 28, 2026
- 340B hospitals spend less on charity care than non-340B hospitals.
- A report highlights a statistically significant difference in spending.
- The findings raise questions about the program’s impact on patient assistance.
340B Rebate Pilot to Start in 2027.
Becker’s Hospital Review · September 28, 2026
- A federal rebate pilot for 340B pricing begins January 1, 2027.
- The model aims to improve claims-level transparency and prevent duplicate discounts.
- HRSA supports the pilot to improve program integrity and accountability.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
| D.N.J. | CAREPOINT HEALTH MANAGEMENT ASSOCIATES LLC v. RWJ BARNABAS HEALTH INC. — Exhibit 4. Case filed September 6, 2022. [source] | September 25, 2026 |
| E.D. Mo. | AbbVie Inc. v. Hanaway — Memorandum and order: Accordingly, the Court grants Intervenors’ motion to intervene. see order for details. Case filed July 22, 2024. [source] | September 24, 2026 |
| M.D. Fla. | Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Memorandum in support re Motion to Dismiss. Case filed July 2, 2026. [source] | September 23, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Objection to 5 motion for Preliminary Injunction Defendant’s Opposition to Plaintiff’s Motion for Preliminary Injunction. Case filed July 27, 2026. [source] | September 17, 2026 |
| 8th Cir. | Novartis Pharmaceuticals Corp. v. Catherine L. Hanaway — Judge order: The petition for rehearing en banc is denied. The petition for panel rehearing is also denied. Case filed March 28, 2025. [source] | September 16, 2026 |
| 8th Cir. | AbbVie, Inc. v. Marty Jackley — Motion to hold briefing schedule in abeyance. Case filed August 11, 2026. [source] | September 15, 2026 |
MANUFACTURER WATCH
| Manufacturer | Action | Date |
|---|---|---|
| Johnson & Johnson | Requires claims-level data submission for 340B pricing compliance. [source] | September 11, 2026 |
WHAT TO WATCH NEXT
- Monitor the impact of the IRA on 340B margins as more drugs are negotiated under the act. [source]
- Watch for legislative developments on the SECURE 340B Act and potential rebate model bans. [source]
- Prepare for the 340B rebate pilot starting January 1, 2027, to assess its impact on operations. [source]
- Stay informed on ongoing 340B litigation affecting program rules and compliance requirements. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.